deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT03309878

Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

A Phase I and Randomized Phase II Study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in Relapsed, Refractory Diffuse Large-B Cell Lymphoma

Sponsor: National Cancer Institute (NCI)

Conditions Recurrent Diffuse Large B-Cell Lymphoma Recurrent High Grade B-Cell Lymphoma Recurrent Transformed B-Cell Non-Hodgkin Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory High Grade B-Cell Lymphoma Refractory Transformed B-Cell Non-Hodgkin Lymphoma
Interventions Mogamulizumab Pembrolizumab
Updated 31 times since 2017 Last updated: Aug 29, 2023 Started: Oct 24, 2018 Primary completion: Jan 6, 2021 Completion: Apr 11, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03309878, this PHASE1/PHASE2 trial focuses on Recurrent Diffuse Large B-Cell Lymphoma and Recurrent High Grade B-Cell Lymphoma and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 31 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jul 2019 · 2 months · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Jan 2020 · 2 months · monthly snapshot~Jan 2020 – ~May 2020 · 4 months · monthly snapshot~May 2020 – ~Jul 2020 · 2 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Nov 2020 · 3 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Sep 2021 · 7 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~May 2022 · 3 months · monthly snapshot~May 2022 – ~Jul 2022 · 2 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Mar 2023 · 6 months · monthly snapshot~Mar 2023 – ~Jul 2023 · 4 months · monthly snapshot~Jul 2023 – ~Sep 2023 · 2 months · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

31 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Oct 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  4. Sep 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Jul 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 26 earlier versions

  1. Mar 2023 — Jul 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Sep 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Jul 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. May 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Feb 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Sep 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Feb 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  8. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE1_PHASE2

  9. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  10. Aug 2020 — Nov 2020 [monthly]

    Recruiting PHASE1_PHASE2

  11. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE1_PHASE2

  12. May 2020 — Jul 2020 [monthly]

    Recruiting PHASE1_PHASE2

  13. Jan 2020 — May 2020 [monthly]

    Recruiting PHASE1_PHASE2

  14. Nov 2019 — Jan 2020 [monthly]

    Recruiting PHASE1_PHASE2

  15. Sep 2019 — Nov 2019 [monthly]

    Recruiting PHASE1_PHASE2

  16. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE1_PHASE2

  17. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE1_PHASE2

  18. May 2019 — Jul 2019 [monthly]

    Recruiting PHASE1_PHASE2

  19. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE1_PHASE2

  20. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE1_PHASE2

  21. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE1_PHASE2

  22. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE1_PHASE2

  23. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE1_PHASE2

  24. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  25. Jun 2018 — Nov 2018 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  26. Oct 2017 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations